Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations

Table 5 Pathological response, n (%)

	RTCh	Ch	P value
	(n = 40)	(n = 27)
No surgery	5 (12.5)	6 (22.2)
Pathological complete response	6 (17.1)	1 (4.8)	0.23
Tumor response1			0.001
0%-10%	19 (54.4)	2 (9.5)
11%-30%	9 (25.7)	2 (9.5)
31%-50%	4 (11.4)	3 (14.3)
51%-70%	2 (5.7)	6 (28.6)
> 70%	1 (2.8)	8 (38.1)
Nodal response1			0.001
0%-10%	30 (85.7)	7 (33.3)
11%-30%	1 (2.8)	0
31%-50%	2 (5.7)	3 (14.3)
51%-70%	0	2 (9.5)
> 70%	2 (5.7)	9 (42.9)
Downstaging	28 (80)	7 (33.3)	0.002

¹According to the percentage of viable cells in the histological study.

Ch: Chemotherapy. RTCh: Radiochemotherapy.